Stockscreener 앱 받기
4.78
6.27%
-0.32
시간 외 거래:
4.78
Sage Therapeutics Inc 주식(SAGE)의 최신 뉴스
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
BB Biotech AG's Strategic Acquisition of Sage Therapeutics Shares - GuruFocus.com
FMR LLC Adjusts Stake in Sage Therapeutics Inc - GuruFocus.com
Easterly Investment Partners LLC Sells 91,500 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
Vanguard Group Inc's Recent Transaction in Sage Therapeutics Inc - GuruFocus.com
Objective long/short (SAGE) Report - Stock Traders Daily
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) sh - GuruFocus.com
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seekin - GuruFocus.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Pinnacle Associates Ltd. Has $1.22 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics Inc Sued for Securities Law ViolationsConta - GuruFocus.com
Sage Therapeutics Reports Q3 Growth and Strategic Focus - TipRanks
Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Citeline News & Insights
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Sage Therapeutics CFO Kimi Iguchi resigns from position - XM
SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures - TipRanks
Cambridge biotech's layoffs will cut dozens of Mass. employees - The Business Journals
HC Wainwright Expects Weaker Earnings for Sage Therapeutics - MarketBeat
What is HC Wainwright's Estimate for SAGE FY2028 Earnings? - MarketBeat
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Call Transcript - Insider Monkey
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler - Yahoo Finance
Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - MedCity News
Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright - TipRanks
Scotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $14.00 - MarketBeat
Sage Therapeutics price target lowered to $14 from $17 at Scotiabank - TipRanks
Sage Therapeutics' (SAGE) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Sage to sunset first postpartum depression drug, focus on Zurzuvae - The Business Journals
Sage Therapeutics (NASDAQ:SAGE) Issues Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates - MSN
Sage stock plunges 18% post-market following business update, earnings - MSN
Sage Therapeutics reports Q3 EPS ($1.53) , consensus ($1.53) - TipRanks
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates - Business Wire
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $13.76 Average PT from Analysts - MarketBeat
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Malaysian Reserve
Deadline on Oct. 28th coming up in Lawsuit for Investors who lost - openPR
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
DEADLINE ALERT for OM, SAGE, and SMCI: The Law Offices of - GlobeNewswire
FINAL SAGE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Sage Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024SAGE - PR Newswire
FINAL REMINDER SAGE DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Sage Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - Stockhouse Publishing
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise - MSN
SAGE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE) - Business Wire
3.66%
1.11%
자본화:
|
볼륨(24시간):